Calcitonin (Enteris BioPharma/Tarsa Therapeutics)

降钙素（Enteris BioPharma / Tarsa Therapeutics）

Report date: 2022/08/29 20:00:24

Base Information

Drug NameCalcitonin (Enteris BioPharma/Tarsa Therapeutics)
Drug Alias NameCalcitonin oralCalcitonin-salmon [rDNA origin] delayed release tabletsOral recombinant salmon calcitoninSalmon calcitonin oralsCT oral +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionCalcitonin receptor agonists
TargetsCalcitonin receptor
Therapy Area/IndicationsOsteoporosis, PostmenopausalOsteoporosisBone Diseases, Metabolic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[6] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUnigene Laboratories Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTarsa Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsOsteoporosis, PostmenopausalOsteoporosisBone Diseases, Metabolic

Other Information

ATC CodeN/A
Related LinksN/A